Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: smh who wrote (3894)	5/29/2001 9:12:06 AM
From: Biomaven	Read Replies (1) of 52153

Here's a comment from JAGnotes on prospects for CRO's (which are something of a proxy for the entire pharmaceutical industry pipeline): Pharmaceutical Services: 2001 Data Shows Uptick in Phase III Development Companies Mentioned: (CVD), (ICLR), (KNDL), (PPDI), (PRXL), (QTRN) . The 2001 Pharmaprojects data shows the first increase in Phase III development activity since 1997. . Phase I and Phase II activity continues to be strong. . Given the strength in Phase I and Phase II growth over the past few years, we expect the Phase III growth to continue over the next few years. . The Pharmaprojects 2001 annual review noted a decrease in the number of discontinued projects. . A recent article in the May 2001 issue of Scrip evaluated the Pharmaprojects data for another purpose, but the underlying analysis appears to support our interpretation. . Given this data, we believe the outlook for the group is positive over the next 3-5 years. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next